Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab

BACKGROUND: We previously reported that in patients with HER2‐positive (HER2+) locally advanced breast cancer treated with neoadjuvant trastuzumab‐containing regimens, high HER2 to centromere enumerator probe 17 ratio on fluorescence in situ hybridization (HER2 FISH ratio) was an independent predict...

Full description

Saved in:
Bibliographic Details
Published in:Oncologist
Main Authors: Kogawa, Takahiro, Fujii, Takeo, Wu, Jimin, Harano, Kenichi, Fouad, Tamer M., Liu, Diane D., Shen, Yu, Masuda, Hiroko, Krishnamurthy, Savitri, Chavez‐MacGregor, Mariana, Lim, Bora, Murthy, Rashmi K., Valero, Vicente, Tripathy, Debu, Ueno, Naoto T.
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Inc. 2020
Subjects:
Breast Cancer
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288623/
https://ncbi.nlm.nih.gov/pubmed/32003919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0611
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items